Bristol-based corporate finance advisory firm Shaw & Co has advised the shareholders of leading UK life science research supplier AMSBIO on its sale to Dutch group Europa Biosite.
Headquartered in Abingdon, Oxfordshire, AMSBIO is a premier provider of life science products and services with expertise in biospecimens, stem cells and 3D cell culture, glycobiology and molecular biology, and an extensive product portfolio. 
Its supports manufacturers, academic groups and revenue-generating biotechs to develop innovative methods, processes, products and medicines globally.
The deal will enable Europa Biosite, a leading European distributor of life science products, to further expand its offering, especially in the fast-growing areas of biospecimens, stem cell research and regenerative medicine.
Europa Biosite employs more than 150 people with offices in Sweden, Austria, Germany, the Netherlands, Switzerland and the UK. 
It is backed by Adelis Equity, a specialist in the healthcare sector that invested in the company in 2021.
The takeover will also facilitate product and customer collaboration between the two companies in Europe, while providing Europa Biosite with access to the globally significant North American market.
Established in 1987, AMSBIO has international offices in Alkmaar in The Netherlands and Cambridge in the US and employs 32 people worldwide.
Shaw & Co CEO and founder Jim Shaw said: “BioPharma is a burgeoning sector for M&A across the globe. We ran a robust competitive process that garnered a huge amount of interest from international investors with Europa Biosite being chosen as the ideal strategic partner to take the company forward.”
Addleshaws Goddard provided legal advice to major shareholder Alex Sim and AMSBIO on the deal, with a team led by Murray Jack and Yavor Georgiev from its Glasgow office.
The deal, financial terms of which have not disclosed, is the latest in the healthcare and life sciences sector to be overseen by Shaw & Co, including the £31.5m sale of CRO Nanopharm to Aptar Pharma, a business focused on respiratory delivery research, and the raising of £40m of funding for small molecule experts CatSci.
The firm, which was founded by Jim Shaw in 2011, has offices in Bristol, Birmingham, Glasgow, London and Manchester.
It specialises in a range of services from exit strategies, business valuations, acquisitions and sales, to mergers, management buy-outs and the securing of finance for growth.
